在雄性大鼠口服同时使用后,2-脱氧葡萄糖和氧氨酸 HPLC-MS-MS 分析方法和药理学相互作用
Dongxiao Sun1,2, Sangyub Kim1, Deepkamal Karelia1
1Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Pharmacology research & perspectives
|January 31, 2024
概括
同时口服2-脱氧葡萄糖 (2-DG) 和氧化 (HCQ) 导致显著的负面药物动力学相互作用,降低了药物暴露. 对于前列腺癌这种联合治疗的临床转化,需要进一步优化.
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 药物新陈代谢 药物新陈代谢
背景情况:
- 之前的研究表明,在前列腺癌模型中,通过腹腔内注射,结合2 - 脱氧葡萄糖 (2-DG),一个六酶抑制剂,和氨酸 (CQ),一种自抑制剂,具有协同的瘤杀伤作用.
- 这些药物在同时口服后的药理动力学 (PK) 概况以前没有被研究过.
研究的目的:
- 为了研究药物相互作用和药物动力学行为 2-deoxyglucose (2-DG) 和基 (HCQ) 在同时口服后.
- 开发和验证用于生物样本中量化2-DG和HCQ的分析方法.
主要方法:
- 在大鼠血清中开发高性能液态染色学-并联质谱法 (HPLC-MS-MS) 方法,用于2-DG和HCQ.
- 在单独服用2-DG,单独服用HCQ或它们的组合后,在 jugular 静脉通道的雄性大鼠中进行药理动力学分析.
- 连续采集血液和分析以确定PK参数,如Tmax,Cmax,AUC,Vd,CL和MRT.
主要成果:
- 通过HPLC-MS-MS方法,可以快速和完全分离2-DG,并准确量化两种药物.
- 同时口服2-DG和HCQ导致2-DG的峰值度 (Cmax) 和曲线下的面积 (AUC) 显著降低,HCQ的AUC降低.
- 该组合改变了2-DG的分布体积 (Vd) 和清除量 (CL),以及HCQ的CL,这表明在肠道吸收水平可能存在负面的药理学相互作用.
结论:
- 当口服2-DG和HCQ同时服用时,它们之间会发生显著的负面药理动力相互作用.
- 这些相互作用可能会影响组合治疗的疗效,需要在未来优化,以便在癌症治疗中临床应用.
- 需要进一步的研究来完善2-DG和HCQ联合使用的剂量策略.
更多相关视频
08:28Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
8.3K
08:31Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
Published on: October 11, 2019
10.3K
相关概念视频
Phase II Reactions: Glucuronidation
428
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
428
Drug Metabolism: Phase II Reactions
3.8K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.8K
